These results suggest that poly ADP ribose polymerase (PARP) inhibition, PI3K/AKT/mTOR pathway inhibitors, EGFR- and HER2-directed therapy, may be promising areas for future research in advanced cervical cancer [118]. The gene discussed is MTOR; the disease is cervical cancer.